Targeting the bone microenvironment in multiple myeloma

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Multiple myeloma (MM) is a plasma cell malignancy characterized by the frequent development of osteolytic lesions, osteopenia, pathological fractures, and/or severe bone pain. In the past few years several potential factors involved in this process have been identified and, with the increased knowledge of the signaling pathways involved in the regulation of normal osteoblast and osteoclast function, have provided us with a better understanding of the contributions of the marrow microenvironment to MM bone disease. These studies have identified several potential novel targets for treating MM bone disease in addition to the current standard treatment of bisphosphonates. In this article, we discuss several potential targets for treating MM bone disease as well as novel therapies that are in clinical trials for these patients.

Original languageEnglish
Pages (from-to)244-250
Number of pages7
JournalJournal of Bone and Mineral Metabolism
Volume28
Issue number3
DOIs
StatePublished - May 2010
Externally publishedYes

Fingerprint

Multiple Myeloma
Bone Diseases
Bone and Bones
Spontaneous Fractures
Metabolic Bone Diseases
Diphosphonates
Osteoclasts
Plasma Cells
Osteoblasts
Bone Marrow
Clinical Trials
Pain
Therapeutics
Neoplasms

Keywords

  • Bisphosphonates
  • Bone microenvironment
  • Cytokines
  • Multiple myeloma
  • Osteoclast

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine

Cite this

Targeting the bone microenvironment in multiple myeloma. / Roodman, G. David.

In: Journal of Bone and Mineral Metabolism, Vol. 28, No. 3, 05.2010, p. 244-250.

Research output: Contribution to journalArticle

@article{014906b566814be699339dfdc19641a8,
title = "Targeting the bone microenvironment in multiple myeloma",
abstract = "Multiple myeloma (MM) is a plasma cell malignancy characterized by the frequent development of osteolytic lesions, osteopenia, pathological fractures, and/or severe bone pain. In the past few years several potential factors involved in this process have been identified and, with the increased knowledge of the signaling pathways involved in the regulation of normal osteoblast and osteoclast function, have provided us with a better understanding of the contributions of the marrow microenvironment to MM bone disease. These studies have identified several potential novel targets for treating MM bone disease in addition to the current standard treatment of bisphosphonates. In this article, we discuss several potential targets for treating MM bone disease as well as novel therapies that are in clinical trials for these patients.",
keywords = "Bisphosphonates, Bone microenvironment, Cytokines, Multiple myeloma, Osteoclast",
author = "Roodman, {G. David}",
year = "2010",
month = "5",
doi = "10.1007/s00774-009-0154-7",
language = "English",
volume = "28",
pages = "244--250",
journal = "Journal of Bone and Mineral Metabolism",
issn = "0910-0067",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Targeting the bone microenvironment in multiple myeloma

AU - Roodman, G. David

PY - 2010/5

Y1 - 2010/5

N2 - Multiple myeloma (MM) is a plasma cell malignancy characterized by the frequent development of osteolytic lesions, osteopenia, pathological fractures, and/or severe bone pain. In the past few years several potential factors involved in this process have been identified and, with the increased knowledge of the signaling pathways involved in the regulation of normal osteoblast and osteoclast function, have provided us with a better understanding of the contributions of the marrow microenvironment to MM bone disease. These studies have identified several potential novel targets for treating MM bone disease in addition to the current standard treatment of bisphosphonates. In this article, we discuss several potential targets for treating MM bone disease as well as novel therapies that are in clinical trials for these patients.

AB - Multiple myeloma (MM) is a plasma cell malignancy characterized by the frequent development of osteolytic lesions, osteopenia, pathological fractures, and/or severe bone pain. In the past few years several potential factors involved in this process have been identified and, with the increased knowledge of the signaling pathways involved in the regulation of normal osteoblast and osteoclast function, have provided us with a better understanding of the contributions of the marrow microenvironment to MM bone disease. These studies have identified several potential novel targets for treating MM bone disease in addition to the current standard treatment of bisphosphonates. In this article, we discuss several potential targets for treating MM bone disease as well as novel therapies that are in clinical trials for these patients.

KW - Bisphosphonates

KW - Bone microenvironment

KW - Cytokines

KW - Multiple myeloma

KW - Osteoclast

UR - http://www.scopus.com/inward/record.url?scp=77956030798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956030798&partnerID=8YFLogxK

U2 - 10.1007/s00774-009-0154-7

DO - 10.1007/s00774-009-0154-7

M3 - Article

C2 - 20127498

AN - SCOPUS:77956030798

VL - 28

SP - 244

EP - 250

JO - Journal of Bone and Mineral Metabolism

JF - Journal of Bone and Mineral Metabolism

SN - 0910-0067

IS - 3

ER -